$-0.27 EPS Expected for MEI Pharma, Inc. (MEIP)

April 21, 2018 - By Michael Collier

Analysts expect MEI Pharma, Inc. (NASDAQ:MEIP) to report $-0.27 EPS on May, 3.They anticipate $0.25 EPS change or 1,250.00 % from last quarter’s $-0.02 EPS. After having $-0.16 EPS previously, MEI Pharma, Inc.’s analysts see 68.75 % EPS growth. The stock decreased 0.92% or $0.02 during the last trading session, reaching $2.15. About 76,572 shares traded. MEI Pharma, Inc. (NASDAQ:MEIP) has risen 32.91% since April 21, 2017 and is uptrending. It has outperformed by 21.36% the S&P500.

MEI Pharma, Inc., an oncology company, focuses on the clinical development of drugs for the treatment of cancer. The company has market cap of $79.66 million. The company??s clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. It currently has negative earnings. The Company’s clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or follicular lymphoma; and ME-344, an isoflavone-derived mitochondrial inhibitor for the treatment of HER2-negative breast cancer.

MEI Pharma, Inc. (NASDAQ:MEIP) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.